Eisai Cuts U.S. Jobs In ‘Realignment’
This article was originally published in PharmAsia News
Executive Summary
Eisai is cutting a little over 200 people from its U.S. commercial and regional corporate services units in what the Japanese pharma firm is dubbing a "realignment of its US operations." The move follows weaker than expected sales for several new drugs.